市場調查報告書
商品編碼
1464760
冷凍和解凍設備市場:按產品、技術、應用和最終用途分類 - 2024-2030 年全球預測Cryoablation Devices Market by Product, Technology, Application, End-Use - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年凍融設備市場規模為4.4342億美元,2024年將達4.9145億美元,2030年將達9.3925億美元,複合年成長率為11.31%。
凍融機是一種專門的醫療設備,用於透過稱為冷凍消融的過程來破壞體內不必要的組織。該技術涉及應用極冷的溫度來瞄準並殺死異常細胞和組織,例如導致心律不整的腫瘤或不規則心臟細胞。該設備通常將冷凍劑(例如液態氮或氬氣)直接輸送到問題區域,冷凍細胞並最終殺死它們。這種方法比傳統外科手術侵入性更小,通常會減少疼痛、加速恢復時間,並降低患者出現併發症的風險。冷凍消融用於多種醫學領域,包括用於治療腫瘤的腫瘤學和用於治療心律不整的心臟科。全球心臟疾病患病率不斷上升,推動了對低溫解凍設備的需求,以實現侵入性較小的治療選擇。然而,對醫務人員進行專門培訓的需要、與設備相關的併發症的可能性以及設備和程序的高成本可能會給製造商帶來主要障礙。由於設備的小型化和影像技術的進步,冷凍消融手術的侵入性變得越來越小。與傳統手術方法相比,患者的恢復時間明顯加快,且併發症風險較低。這在治療敏感或難以到達的區域時特別有用。
主要市場統計 | |
---|---|
基準年[2023] | 4.4342億美元 |
預計年份 [2024] | 4.9145億美元 |
預測年份 [2030] | 9.3925億美元 |
複合年成長率(%) | 11.31% |
產品利用表皮和皮下凍融系統來冷凍和破壞皮膚中的異常組織
表皮和皮下冷凍系統治療皮膚表面或皮膚表面以下的病灶和異常。這種類型的治療通常用於治療皮贅、疣和某些小的表淺腫瘤等疾病。透過對目標區域進行精確冷卻,可以有效地冷凍和破壞有問題的組織,而不會對周圍的健康組織造成重大損害。另一方面,組織接觸式探頭消融裝置的特徵是其直接接觸方式,直接對需要治療的組織施加冷和熱。這種方法可以進行受控的局部冷凍,適用於治療體內疾病,例如某些癌症腫瘤和異常心臟組織。組織噴射探針消融裝置採用不同的方法,將冷卻劑直接噴射到組織表面。當需要治療較大區域或需要靈活應用的手術情況時,此方法非常有用。與其他凍融設備一樣,噴霧探頭的工作原理是冷凍和破壞不需要的或生病的組織。使用低溫來瞄準和去除不需要的組織,同時最大限度地減少對周圍健康區域的損害,在各個醫學領域越來越受到關注。
應用:凍融設備擴大用作各種癌症治療中的微創手術選擇。
凍融機徹底改變了多種癌症的治療,包括乳癌、腎臟癌、肝癌、肺癌和攝護腺癌。這些設備使用低溫來破壞癌細胞,並為傳統手術方法提供侵入性較小的替代方案。對於乳癌,冷凍消融可以瞄準並切除小腫瘤,從而可能減少對更具侵入性手術的需求。在腎癌和肝癌中,冷凍消融的精確性可以破壞癌組織,同時保留健康的周圍組織,考慮到這些器官的複雜功能,這一點特別有益。對於肺癌,冷凍消融是因腫瘤位置或潛在疾病而不適合手術的患者的一種治療選擇。同樣,在前列腺癌中,冷凍消融提供了一種有針對性的方法,可以最大限度地減少對周圍神經和組織的損害,避免更多侵入性手術造成的潛在風險,降低尿失禁和勃起功能障礙的風險。將冷凍解凍設備應用於治療這些癌症可為患者帶來潛在的好處,例如縮短恢復時間、降低併發症發生率和保留器官功能,使其成為腫瘤治療的重要工具。
區域洞察
美洲地區,尤其是美國和加拿大,由於醫療基礎設施發達且注重研究和創新,凍融設備的採用率很高。這些地區消費者的需求是由對微創治療方案的需求以及對冷凍消融益處(包括更快的恢復時間)的認知的提高所驅動的。歐洲、中東和非洲地區先進的醫療基礎設施和嚴格的法規確保了高安全和品質標準,為凍融設備的採用奠定了基礎。市場人口老化以及癌症和心臟病的高盛行率使得冷凍消融成為一種有價值的治療選擇。在快速發展的醫療基礎設施、不斷提高的健康意識和不同的監管環境的推動下,亞太地區是一個充滿活力的冷凍和解凍設備市場。中國和日本處於這方面的前沿,在醫療保健領域進行了大量投資,並且越來越多的本土製造商進入冷凍消融市場。與之相輔相成的是政府對醫療保健創新的支持以及冷凍消融治療疾病盛行率的不斷上升。印度正在成為一個潛在市場,醫療保健成本不斷上升,以及改善醫療服務的努力推動了對包括冷凍消融在內的先進治療方法的需求。
FPNV定位矩陣
FPNV定位矩陣對於評估凍融設備市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對凍融設備市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.凍融設備市場規模及預測如何?
2.在冷凍和解凍設備市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.凍融設備市場的技術趨勢與法規結構是什麼?
4.凍融設備市場主要供應商的市場佔有率為何?
5.進入凍融設備市場的合適型態和策略手段是什麼?
[198 Pages Report] The Cryoablation Devices Market size was estimated at USD 443.42 million in 2023 and expected to reach USD 491.45 million in 2024, at a CAGR 11.31% to reach USD 939.25 million by 2030.
Cryoablation devices are specialized medical instruments used to destroy unwanted tissues in the body through a process known as cryoablation. This technique involves the application of extremely cold temperatures to target and kill abnormal cells or tissues, such as tumors or irregular cardiac cells, that can lead to arrhythmias. The device typically delivers a freezing agent, such as liquid nitrogen or argon gas, directly to the problematic area, causing the cells to freeze and eventually die. This method is minimally invasive compared to traditional surgical procedures, often resulting in less pain, shorter recovery times, and reduced patient complications risk. Cryoablation is used in various medical fields, including oncology, for treating tumors and cardiology, for managing heart rhythm disorders, among others. The growing prevalence of cancer and cardiac diseases globally boosts the demand for cryoablation devices for less invasive treatment options. However, the need for specialized training for practitioners and the potential for device-related complications, along with the high expense of devices and procedures, can present a significant hurdle for the manufacturers. Advancements in device miniaturization and imaging technology have made cryoablation procedures less invasive. Patients have significantly shorter recovery times and lower complication risks than traditional surgical methods. This is particularly beneficial in treating conditions within delicate or hard-to-reach areas.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 443.42 million |
Estimated Year [2024] | USD 491.45 million |
Forecast Year [2030] | USD 939.25 million |
CAGR (%) | 11.31% |
Product: Utilization of epidermal & subcutaneous cryoablation systems in freezing and destroying skin abnormal tissue
Epidermal and subcutaneous cryoablation systems treat lesions or abnormalities on the skin's surface or just below it. This type of treatment is often used for conditions like skin tags, warts, and certain small, superficial tumors. By delivering precise cooling to the targeted area, these devices effectively freeze and destroy the problematic tissue without significant damage to the surrounding healthy tissue. On the other hand, tissue contact probe ablator devices are characterized by their direct contact method, which delivers the cold temperature directly applied to the tissue requiring treatment. This approach allows for controlled and localized freezing, making it suitable for treating conditions within the body, such as certain cancerous tumors or abnormal cardiac tissues. Tissue spray probe ablator devices utilize a different approach by spraying a cooling agent directly onto the tissue surface. This method is helpful in cases where a broader area needs to be treated or in surgical situations where flexible application is necessary. Like the other cryoablation devices, the spray probe also works to freeze and destroy unwanted or diseased tissues. By using extreme cold, these devices target and eliminate unwanted tissues while minimizing damage to surrounding healthy areas, making them an increasingly popular choice in various medical fields.
Application: Increasing usage of cryoablation devices as a minimally invasive surgical option in varied cancer treatments
Cryoablation devices are innovative in treating various cancers, including breast, kidney, liver, lung, and prostate. These devices utilize extreme cold to destroy cancer cells, offering a minimally invasive alternative to traditional surgical methods. In breast cancer, cryoablation can target and eliminate small tumors, potentially reducing the need for more invasive surgeries. For kidney and liver cancer, the precision of cryoablation allows for the destruction of cancerous tissue while preserving healthy surrounding tissue, which can be particularly beneficial given the complex functions of these organs. In the context of lung cancer, cryoablation presents a treatment option for patients who may not be candidates for surgery due to the location of the tumor or underlying health conditions. Similarly, in prostate cancer, cryoablation offers a targeted approach that can minimize damage to surrounding nerves and tissues, reducing the risk of urinary incontinence and erectile dysfunction that can result from more invasive procedures. The application of cryoablation devices in treating these cancers highlights an essential advancement in oncological care, offering patients potential benefits such as reduced recovery times, lower complication rates, and preservation of organ function.
Regional Insights
In the Americas, with a particular focus on the United States and Canada, there is a high adoption rate of cryoablation devices primarily due to the well-established healthcare infrastructure and a strong focus on research and innovation. Consumer need in these regions is driven by a demand for minimally invasive treatment options and a growing awareness of cryoablation's benefits, such as reduced recovery time. The EMEA's sophisticated healthcare infrastructure and stringent regulations ensuring high safety and quality standards set the stage for adopting cryoablation devices. The market is driven by an aging population and a high prevalence of cancer and cardiological diseases, making cryoablation a valuable treatment option. The Asia Pacific region exhibits a dynamic market for cryoablation devices, driven by a mix of rapidly developing healthcare infrastructure, increasing health awareness, and varying regulatory landscapes. China and Japan are at the forefront, with significant investments in healthcare and a growing number of local manufacturers entering the cryoablation market. This is complemented by government support for healthcare innovation and a rising incidence of conditions treatable with cryoablation. India is emerging as a potential market, with increasing healthcare expenditure and initiatives to improve healthcare access, driving the demand for advanced treatment methods, including cryoablation.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Cryoablation Devices Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cryoablation Devices Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Cryoablation Devices Market, highlighting leading vendors and their innovative profiles. These include AtriCure, Inc., Boston Scientific Corporation, BVM Medical Limited, ConMed Corporation, CooperSurgical, Inc., CRYO SCIENCE SP. Z OO, CryoConcepts LP, CryoLife, Inc., GE HealthCare Technologies Inc., IceCure Medical Ltd., Integer Holdings Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, Merit Medical Systems, Inc., METRUM CRYOFLEX Sp. z o.o., MicroPort Scientific Corporation, Olympus Corporation, Quantum Surgical SAS, Smith & Nephew PLC, Stryker Corporation, and Varian Medical Systems, Inc. by Siemens Healthineers AG.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Cryoablation Devices Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cryoablation Devices Market?
3. What are the technology trends and regulatory frameworks in the Cryoablation Devices Market?
4. What is the market share of the leading vendors in the Cryoablation Devices Market?
5. Which modes and strategic moves are suitable for entering the Cryoablation Devices Market?